| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5898683 | Diabetes Research and Clinical Practice | 2016 | 8 Pages |
Abstract
Current evidence suggests that higher baseline HbA1c is associated with a greater efficacy of both DPP-4I and GLP-1A therapies in lowering HbA1c. The roles of other potential predictors are less consistent across studies and require further investigation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Helene Bihan, Winda L. Ng, Dianna J. Magliano, Jonathan E. Shaw,